DoD Breast Cancer, Breakthrough Award Levels 1 and 2 | W81XWH 21 BCRP BTA12

Opportunity Information: Apply for W81XWH 21 BCRP BTA12

The DoD Breast Cancer Research Program (BCRP) Breakthrough Award Levels 1 and 2 (Funding Opportunity Number W81XWH-21-BCRP-BTA12) is a discretionary research funding opportunity administered by the Department of Defense through the U.S. Army Medical Research Acquisition Activity (USAMRAA). It supports science and technology and other research and development activities (CFDA 12.420) through either grants or cooperative agreements. The central purpose of the Breakthrough Award mechanism is to back breast cancer research that is genuinely positioned to change what is possible in the field, not just add incremental knowledge. Projects funded under this mechanism are expected to have high potential to lead to, or directly make, breakthroughs that meaningfully accelerate progress toward ending breast cancer.

A defining requirement of the program is “impact.” The program is explicitly looking for research that could produce a major shift in prevention, detection, diagnosis, prognosis, treatment, survivorship, or another clinically relevant area within the breast cancer landscape. The expected impact can be near-term or long-term, but it must move beyond a minor advancement and should be plausibly capable of enabling a new approach that is fundamentally better than interventions that are already approved or already moving through clinical development. Another consistent expectation is patient relevance: applications should clearly identify the breast cancer patient population, or individuals at risk of breast cancer, who would ultimately benefit if the work succeeds. In other words, the proposal should connect the science to a defined end user group rather than staying abstract.

The Breakthrough Award is organized into multiple funding levels, each tied to a specific research scope and stage on the path toward clinical application. Applicants are expected to choose the appropriate level based on the scope described in the program announcement rather than choosing a level simply to match a desired budget. Within this opportunity, the focus is on Levels 1 and 2. Level 1 is aimed at innovative, high-risk/high-reward ideas that are still early in their development, including untested theories that tackle an important breast cancer problem. The program is intentionally structured to encourage bold concepts at this stage, so preliminary data are not required for Level 1. The anticipated outcome for Level 1 is proof of concept, meaning applicants should lay out a credible plan to demonstrate that the core idea works and is worth advancing.

Level 2 is positioned later on the development pathway and is meant for research that already has substantial preliminary or published data behind it. A Level 2 application should do more than show an interesting signal; it should strongly validate that the work is ready for clinical translation within a well-defined breast cancer context. That “well-defined context” matters, because the program is looking for a clear rationale for how the work fits into the breast cancer landscape and how it could realistically progress toward clinical use. The opportunity also highlights Level 2 projects in population science and prevention. These studies can be particularly resource-intensive because they often involve human subjects and/or human biospecimens, and the announcement notes that, with compelling justification, population science and prevention proposals may be able to request a higher level of funding and an additional year of performance to accommodate those demands.

A notable feature of this funding mechanism is the Partnering PI Option, which is designed to support applications led by two principal investigators working as true collaborators. Under this structure, one investigator serves as the Initiating PI and handles most submission-related administration, while the other serves as the Partnering PI. The intent is not to create a nominal partnership but to fund genuinely integrated team science. Both PIs are expected to contribute substantially to the project design and the key application components, including the project narrative and the statement of work, and the application should show that both investigators have equal intellectual input. The program also expects similar and appropriate levels of effort from each PI, and it anticipates that funding will be balanced between the two unless the application provides a strong justification for an uneven split.

The announcement is also clear about what does not count as an acceptable “partnering” relationship. A mentor-trainee pairing, such as a mentor and their current postdoctoral fellow or junior investigator serving as the two PIs, does not match the intent of the option. Likewise, arrangements where one PI mainly provides materials (samples, animal models, investigational agents) while the other PI performs most of the experiments and analyses are discouraged, because they do not represent a balanced, co-led scientific partnership. The program encourages new partnerships but does not require them, and it cautions against listing the same person as a Partnering PI on multiple Level 1 and 2 Breakthrough Award applications unless those applications clearly address distinct research questions. If an application using the Partnering PI Option is selected for funding, each PI is expected to be named on an individual award within the recipient organization, reinforcing the idea that both investigators are being supported as co-leaders rather than as a primary PI plus a subcontract-like contributor.

In terms of eligibility and competitiveness, the opportunity is listed as unrestricted, meaning it is open to any type of entity unless additional eligibility limitations are stated elsewhere in the full announcement. Regardless of the structure (single PI or partnering PIs), applications are expected to propose an appropriate and robust research team with the combined expertise and breast cancer-relevant background needed to execute the work successfully. Administrative details provided in the source information include the original posting date of January 6, 2021, an original closing date of March 25, 2021, and an expectation of approximately 21 awards, with an award ceiling not specified in the summary data. Overall, the opportunity is best understood as a pathway-driven, impact-first breast cancer research award that funds either bold early proof-of-concept ideas (Level 1) or well-supported, translationally ready projects (Level 2), with an added emphasis on meaningful collaboration when the two-PI model is used.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Breast Cancer, Breakthrough Award Levels 1 and 2" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jan 06, 2021.
• Applicants must submit their applications by Mar 25, 2021. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 21 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 21 BCRP BTA12

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: